ObsEva

Read more
Brian O’Callaghan's photo - CEO of ObsEva

CEO

Brian O’Callaghan

CEO Approval Rating

85/100

Founded:

2012

Status:

PublicIndependent CompanyNASDAQOBSN

OBSEVA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

ObsEva's company profile
Brian O’Callaghan's photo - CEO of ObsEva

Brian O’Callaghan

CEO

85/100
45
$326.3M
$ < 1M
View Profile
1
ObsEva's Competitor - Evofem logo
Saundra Pelletier's photo - CEO of Evofem

Saundra Pelletier

CEO

100/100
30
$249.3M
$3.4M
View Profile
2
ObsEva's Competitor - Myovant Sciences logo
David Marek's photo - CEO of Myovant Sciences

David Marek

CEO

90/100
20
$958M
$67M
View Profile
3
ObsEva's Competitor - AbbVie logo
Richard A. Gonzalez's photo - Chairman & CEO of AbbVie

Richard A. Gonzalez

Chairman & CEO

88/100
30,000
$6B
$53.7B
View Profile
4
ObsEva's Competitor - PregLem S.A. logo
Ksenija Pavletic Aranicki's photo - CEO of PregLem S.A.

Ksenija Pavletic Aranicki

CEO

84/100
40
$59.9M
$15.7M
View Profile
5
ObsEva's Competitor - ASCEND Therapeutics logo
Nicholas Hart's photo - President & CEO of ASCEND Therapeutics

Nicholas Hart

President & CEO

82/100
900
- -
$14M
View Profile
6
ObsEva's Competitor - Agile Therapeutics logo
Alfred Altomari's photo - Chairman & CEO of Agile Therapeutics

Alfred Altomari

Chairman & CEO

90/100
13
$192.5M
$4.7M
View Profile
7
ObsEva's Competitor - TherapeuticsMD logo
Robert G. Finizio's photo - Co-Founder & CEO of TherapeuticsMD

Robert G. Finizio

Co-Founder & CEO

90/100
241
$322.5M
$84.8M
View Profile
8
ObsEva's Competitor - rEVO Biologics logo
Yann Echelard's photo - CEO of rEVO Biologics

Yann Echelard

CEO

69/100
18
- -
$33.1M
View Profile
9
ObsEva's Competitor - Celmatix logo
Piraye Yurttas Beim's photo - Founder & CEO of Celmatix

Piraye Yurttas Beim

Founder & CEO

70/100
76
$20.4M
$22M
View Profile
10
ObsEva's Competitor - Duchesnay Inc. logo
CEO Avatar

Dean Hopkins

General Manager

- -
100
- -
$21M
View Profile
11
ObsEva's Competitor - Repros Therapeutics logo
CEO Avatar

Larry Dillaha

President & CEO

75/100
24
- -
$ < 1M
View Profile
12
ObsEva's Competitor - Forendo Pharma logo
Risto Lammintausta's photo - Co-Founder & CEO of Forendo Pharma

Risto Lammintausta

Co-Founder & CEO

89/100
21
$33.8M
$2.4M
View Profile

Missing a competitor? Contribute!

Evofem is a top competitor of ObsEva. Evofem was founded in 2009, and is headquartered in San Diego, California. Like ObsEva, Evofem also competes in the Biotechnology field. Evofem generates $7.4M more revenue vs. ObsEva.

Myovant Sciences is seen as one of ObsEva's top competitors. Myovant Sciences is headquartered in Brisbane, California, and was founded in 2016. Like ObsEva, Myovant Sciences also operates in the Biotechnology field. Myovant Sciences generates 966,188% the revenue of ObsEva.

AbbVie has been one of ObsEva's top competitors. AbbVie's headquarters is in North Chicago, Illinois, and was founded in 2013. Like ObsEva, AbbVie also works within the Biotechnology industry. AbbVie generates 315,935,294% of ObsEva's revenue.

ObsEva Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

ObsEva's revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 4.2B. Over the last two quarters, ObsEva's revenue has grown by 100%. Specifically, in Q4 2020's revenue was $ < 1M; in Q3 2020, it was $ < 1M.

ObsEva Acquisitions

No recent acquisitions found related to ObsEva

ObsEva Funding History

Since ObsEva was founded in 2012, it has participated in 6 rounds of funding. In total ObsEva has raised $326.2M. ObsEva's last funding round was on Aug 2019 for a total of $75.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2019
$75M
Private Placement
Oct 2017
$60M
-
IPO
Jan 2017
$96.8M
-
Series B
Nov 2015
$60M
Series A
Aug 2013
$34.5M

Since ObsEva was founded in 2012, it has participated in 6 rounds of funding. In total ObsEva has raised $326.2M. ObsEva's last funding round was on Aug 2019 for a total of $75.0M

ObsEva Investments

No recent investments found related to ObsEva

ObsEva News

August 5, 2021MarketScreener

Q2 Half Year Report 2021

(marketscreener.com) Half-Year report 2021 Interim Condensed Consolidated IFRS Financial Statements f... See more »
August 5, 2021Seeking Alpha

ObsEva EPS beats by $0.01

August 5, 2021BioSpace

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve wome... See more »
August 4, 2021FinanzNachrichten

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomi... See more »
August 3, 2021FinanzNachrichten

ObsEva to Present at Upcoming Investor Conferences

GENEVA, Switzerland August 3, 2021 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company... See more »
August 1, 2021startupticker

ObsEva receives USD 500 million in upfront and milestone payments

ObsEva, a biopharmaceutical company dedicated to improving women's reproductive health and Organon, a... See more »
July 27, 2021MarketScreener

ObsEva Shares Buoyed After License Agreement With Organon

(marketscreener.com) By Robb M. Stewart ObsEva SA has agreed to licence the global development, manuf... See more »

ObsEva Press Releases

October 31, 2018GlobeNewswire

ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018

Geneva, Switzerland and Boston, MA -October 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss ... See more »
January 5, 2018StreetInsider

ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018

ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and c... See more »
August 14, 2017econotimes

ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update

ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and c... See more »

Social Media

ObsEva Headquarters

Chemin des Aulx, 12

Plan-les-Ouates, Geneva1228

41-22-552-3840

Driving Directions »

Trending Companies

ObsEva Summary

ABOUT

Overview

ObsEva is a biopharmaceutical company that develops and commercializes novel therapeutics for woman’s reproductive health and pregnancy. ObsEva was founded in 2012. ObsEva's headquarters is located in Plan-les-Ouates, Geneva, CH 1228. It has raised 32...

CEO

ObsEva's CEO, Brian O’Callaghan, currently has an approval rating of 85%. ObsEva's primary competitors are Evofem, Myovant Sciences & AbbVie.

Website

obseva.com

Frequently Asked Questions about ObsEva

  1. When was ObsEva founded?

    ObsEva was founded in 2012
  2. Who is ObsEva's CEO?

    ObsEva's CEO is Brian O’Callaghan
  3. How much revenue does ObsEva generate?

    ObsEva generates $ < 1M in revenue
  4. How much funding does ObsEva have?

    ObsEva has historically raised $326.3M in funding
  1. Where is ObsEva's headquarters?

    ObsEva's headquarters is in Plan-les-Ouates Geneva, CH
  2. How many employees does ObsEva have?

    ObsEva has 45 employees
  3. What sector does ObsEva operate in?

    ObsEva is in Biotechnology, Pharmaceuticals
  4. Who are ObsEva's competitors?

    ObsEva's top competitors are Evofem, Myovant Sciences, AbbVie